SEARCH WITHIN CONTENT
Citation Information : Immunohematology. Volume 33, Issue 1, Pages 22-26, DOI: https://doi.org/10.21307/immunohematology-2019-005
License : (Transfer of Copyright)
Published Online: 09-October-2019
Daratumumab is an antibody currently used in the treatment of patients with refractory multiple myeloma. Blood samples from patients being treated with daratumumab may show panreactivity during pre-transfusion testing. To facilitate the provision of blood components for such patients, it is recommended that a baseline phenotype or genotype be established prior to starting treatment with daratumumab. If patient red blood cells (RBCs) require phenotyping after the start of daratumumab treatment, dithiothreitol (DTT) treatment of the patient’s RBCs should be performed. The medical charts of four patients treated with daratumumab were reviewed. The individual number of doses ranged from 1 to 14; patient age ranged from 55 to 78 years; two men and two women were included in the review. Type and screen data were obtained from samples collected over 33 encounters with a range of 1 to 13 encounters per patient. All samples were tested initially by automated solid-phase testing. Any reactivity with solid phase led to tube testing with either low-ionicstrength saline, polyethylene glycol, or both. If incubation failed to eliminate the reactivity, the sample was sent to a reference laboratory for DTT treatment and phenotyping. Of the 33 samples tested, 23 (69.7%) samples had reactivity in solid-phase testing. In 8 of the 10 samples that did not react in solid-phase, testing was conducted more than four half-lives after the last dose of daratumumab. Of the 23 that had reactivity in solid-phase, 16 (69.6%) samples demonstrated loss of reactivity using common laboratory methods. For the seven patients whose sample reactivity was not initially eliminated, six were provided with phenotypically matched blood based on prior molecular testing. Only one sample was sent out for DTT treatment. These results suggest that daratumumab interference with pre-transfusion testing can be addressed using common laboratory methods. This finding could save time and money for laboratories that do not have DTT available.
1. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551–60.
2. De Vooght KMK, Oostendorp M, Van Solinge WW. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing. Curr Opin Hematol 2016;23:557–62.
3. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015;55:1545–54.
4. van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 2016;127:681–96.
5. Mehta K, Shahid U. CD38: a cell-surface protein with multiple functions. FASEB J 1996;10:1408–17.
6. AABB Association Bulletin #16-02 Mitigating the Anti-CD38 Interference with Serologic Testing. 2016. Available from https://www.aabb.org/programs/publications/bulletins/ Documents/ab16-02.pdf.
7. Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion 2016;12: 2964–72.
8. Cooling L, Downs T. Immunohematology. In: Hutchinson R, McPherson R, Schexneider K, eds. Henry’s clinical diagnosis and management by laboratory methods. 22nd ed. Philadelphia, PA: Elsevier Saunders 2011:674–730.
9. Schmidt AE, Kirkley S, Patel N, et al. An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab. Transfusion 2015;55:2292–3.
10. Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, eds. Technical manual. 18th ed. Bethesda, MD: AABB, 2014.